PROKIDNEY CORP (PROK)

KYG7S53R1049 - Common Stock

4.32  0 (0%)

After market: 4.66 +0.34 (+7.87%)

PROKIDNEY CORP

NASDAQ:PROK (9/27/2023, 7:00:01 PM)

After market: 4.66 +0.34 (+7.87%)

4.32

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)11-07 2023-11-07/amc
Ins Owners0.22%
Inst Owners64.65%
Market Cap266.07M
Shares61.59M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86.67
IPO06-30 2021-06-30
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PROK Daily chart

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 87 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. The company is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

Company Info

PROKIDNEY CORP

2000 Frontis Plaza Blvd., Suite 250

Winston-Salem NORTH CAROLINA

P: 13369997028.0

Employees: 87

Website: https://prokidney.com/

PROK News

News Image6 days ago - Seeking AlphaChamath Palihapitiya discloses sale of 1.7M ProKidney shares (NASDAQ:PROK)

Chamath Palihapitiya, a 10% owner of ProKidney (PROK), sells 1.7 million shares for $9.3 million. He now owns 2,073,000 shares. Limited recent trading activity.

News Image8 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

News Image14 days ago - Market News VideoRelative Strength Alert For ProKidney
News Image23 days ago - ProKidneyProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
News Image23 days ago - ProKidneyProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...

News Imagea month ago - InvestorPlace3 Biotech Stocks Due for a Massive Short Squeeze

These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters.

PROK Twits

Here you can normally see the latest stock twits on PROK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example